Coya Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Coya Therapeutics CEO'su Arun Swaminathan, Nov2024 tarihinde atandı, in görev süresi 1.58 yıldır. in toplam yıllık tazminatı $ 2.09M olup, şirket hissesi ve opsiyonları dahil olmak üzere 26.1% maaş ve 73.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.043% ine doğrudan sahiptir ve bu hisseler $ 44.20K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 2.9 yıldır.

Anahtar bilgiler

Arun Swaminathan

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi	26.11%
CEO görev süresi	1.6yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	2.9yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Sep 16

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, Coya...

Seeking Alpha • Feb 13

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Summary Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's, providing significant financial derisking and expanding its pipeline. The company has proven its ability to execute business development activities and is in a strong position for upcoming clinical success and potential regulatory approval. Multiple catalysts such as Alzheimer's topline data or additional business development deals could move shares higher. Read the full article on Seeking Alpha

Seeking Alpha • Jan 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Summary Coya Therapeutics is targeting inflammation in neurological diseases by modulating the function of regulatory T cells. The company has decided to put its lead asset, COYA 101, on hold due to cash problems and focus on other assets in early stage studies. Preliminary data from COYA 302 in ALS and COYA 301 in Alzheimer's disease show promising results, but the company's low cash balance poses a risk. Read the full article on Seeking Alpha

Analiz Makalesi • Sep 06

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • May 17

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

CEO Tazminat Analizi

Arun Swaminathan'un ücretlendirmesi Coya Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	-US$21m
Dec 31 2025	US$2m	US$546k	-US$21m
Sep 30 2025	n/a	n/a	-US$18m
Jun 30 2025	n/a	n/a	-US$20m
Mar 31 2025	n/a	n/a	-US$17m
Dec 31 2024	US$1m	US$442k	-US$15m

Tazminat ve Piyasa: Arun 'nin toplam tazminatı ($USD 2.09M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 641.77K ).

Tazminat ve Kazançlar: Arun şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Arun Swaminathan (57 yo)

1.6yrs

Görev süresi

US$2,091,007

Tazminat

Dr. Arun Swaminathan, Ph.D. is Chief Executive Officer of Coya Therapeutics, Inc. from November 1, 2024 and serves as its Director since August 2024. Dr. Swaminathan was Chief Business Officer of Coya Ther...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Arun Swaminathan	CEO & Director	1.6yrs	US$2.09m	0.043% $ 44.2k
Fred Grossman	President & Chief Medical Officer	2.9yrs	US$1.46m	0.012% $ 12.0k
David Snyder	CFO & COO	4.3yrs	US$1.37m	0.038% $ 38.9k
Aaron Thome	Head of Neuroinflammation Platform	no data	Veri yok	Veri yok
Michelle Frazier	Senior Vice President of Regulatory	no data	Veri yok	Veri yok
Karen King	Senior VP of Program Management & Clinical Operations	1.7yrs	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim: COYA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Arun Swaminathan	CEO & Director	1.8yrs	US$2.09m	0.043% $ 44.2k
Dov Goldstein	Independent Director	5.3yrs	US$109.02k	0.043% $ 44.2k
Wilbur Ross	Independent Director	2.6yrs	US$85.27k	0.70% $ 729.4k
Mark Pavao	Independent Director	less than a year	Veri yok	Veri yok
Ann Lee	Independent Director	5yrs	US$97.77k	0.075% $ 77.3k
Merit Cudkowicz	Clinical Advisor	2.9yrs	Veri yok	Veri yok
Dieter Weinand	Independent Director	2.8yrs	US$98.52k	0% $ 0
Anabella Villalobos	Independent Director	5.1yrs	US$99.02k	0.043% $ 44.2k

2.9yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: COYA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/07 23:31
Gün Sonu Hisse Fiyatı	2026/06/05 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Coya Therapeutics, Inc. 9 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Thomas Shrader	BTIG
Keay Nakae	Chardan Capital Markets, LLC
Jason Kolbert	D. Boral Capital LLC.

Coya Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Coya Therapeutics, Inc., Annual General Meeting, Jun 25, 2026

High number of new directors

Coya Therapeutics, Inc. Announces Board Changes

Coya Therapeutics, Inc., Annual General Meeting, Jun 26, 2025

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Recent updates

New major risk - Revenue and earnings growth

Consensus estimates of losses per share improve by 16%

New major risk - Revenue and earnings growth

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Coya Therapeutics, Inc., Annual General Meeting, Jun 25, 2026

Coya Therapeutics, Inc. Is Receives FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

High number of new directors

Coya Therapeutics, Inc. Announces Board Changes

Consensus revenue estimates increase by 14%, EPS downgraded

New minor risk - Market cap size

Coya Therapeutics, Inc. Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia Supporting Mechanistic Rationale for Coya 302 Immune-Restoring Therapy

New major risk - Shareholder dilution

Coya Therapeutics, Inc. announced that it expects to receive $11.099999 million in funding from Greenlight Capital, Inc., Dr. Reddy's Laboratories Inc.

New minor risk - Market cap size

Coya Therapeutics, Inc. Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia

Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als

Consensus revenue estimates increase by 22%

Consensus EPS estimates upgraded to US$1.28 loss

New minor risk - Shareholder dilution

Coya Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $20.000002 million.

Coya Therapeutics, Inc. Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System Anti-Inflammatory Effects and Systemic Regulatory T Cell Enhancing Effects in a Preclinical Animal Inflammation Model

Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?

Coya Therapeutics' Coya 302 Als Trial Accepted by Neals as A Neals-Affiliated Trial

Consensus revenue estimates increase by 478%

Coya Therapeutics, Inc. Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Coya Therapeutics, Inc. Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

New major risk - Revenue and earnings growth

Coya Therapeutics Inc. Provides Additional Non-Clinical Data to Support the Initiation of A Planned Clinical Study Entitles Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label Extension

Price target increased by 8.1% to US$16.75

Coya Therapeutics, Inc., Annual General Meeting, Jun 26, 2025

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

New minor risk - Market cap size

We Think Coya Therapeutics (NASDAQ:COYA) Can Afford To Drive Business Growth

Coya Therapeutics, Inc. Reports Progress from Academic Supported First-in-Class Treg-Derived Exosome Program

Consensus EPS estimates upgraded to US$1.01 loss

New minor risk - Shareholder dilution

Coya Therapeutics, Inc. Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics, Inc. Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (Ld Il-2) + Ctla4-Ig Fusion Protein in Patients with Frontotemporal Dementia (Ftd)

New minor risk - Market cap size

Consensus revenue estimates decrease by 27%, EPS upgraded

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Coya Therapeutics, Inc. announced that it expects to receive $10.000027 million in funding

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Consensus EPS estimates fall by 10%

New minor risk - Share price stability

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Consensus revenue estimates fall by 24%

Coya Therapeutics, Inc. Submits an Investigational New Drug Application

Consensus revenue estimates fall by 44%

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

New major risk - Shareholder dilution

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

Consensus revenue estimates increase by 64%, EPS downgraded

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Consensus revenue estimates increase by 100%

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position